Abdulameer Aseel Hadi, Sulaiman Syed Azhar Bin Syed, Kader Muhamad Bin Sk Abdul
Postgraduate Student, Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Professor, Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
J Clin Diagn Res. 2017 Mar;11(3):OC21-OC24. doi: 10.7860/JCDR/2017/23829.9483. Epub 2017 Mar 1.
Warfarin is an oral anticoagulant which is associated with a decrease in Bone Mass Density (BMD).
The study aimed to explore the prevalence of osteoporosis conditions in Malaysians with chronic warfarin patients using calcaneal quarter of Quantitative Ultrasound (QUS) machine and to investigate whether long-term sodium warfarin therapy that antagonizes vitamin K is affecting the increasing rate of osteoporosis in Penang and to find the risk factors of getting osteoporosis among warfarin users and its non users.
A case-control study was conducted among 130 patients using warfarin, attending the outpatient clinic at Hospital Pulau Pinang. A convenience sampling method was used to recruit the required sample. Another 140 subjects were selected from the community as a control group (non-users of warfarin).
This study showed that more than three-quarter patients (82%) were at high risk of abnormal BMD. The warfarin users were two times more likely to have a higher osteoporosis risk compared to control group. Moreover, BMD has a negative correlation with age, but has a positive correlation with Body Mass Index (BMI). Patients showed a negative correlation with a higher dose of warfarin intake.
This study concluded that osteopenia and osteoporosis are serious problems between users and non-users warfarin in Penang. Therefore, it should be taken into consideration in the Malaysian Health Ministry's agenda.
华法林是一种口服抗凝剂,与骨密度(BMD)降低有关。
本研究旨在利用定量超声(QUS)仪的跟骨部位,探讨慢性华法林治疗的马来西亚患者骨质疏松症的患病率,调查在槟城长期使用拮抗维生素K的华法林钠治疗是否会影响骨质疏松症的发生率,并找出华法林使用者及其非使用者中患骨质疏松症的危险因素。
对130名使用华法林的患者进行了一项病例对照研究,这些患者在槟城医院门诊就诊。采用便利抽样方法招募所需样本。另外从社区中选取140名受试者作为对照组(非华法林使用者)。
本研究表明,超过四分之三的患者(82%)骨密度异常风险较高。与对照组相比,华法林使用者患骨质疏松症的风险高出两倍。此外,骨密度与年龄呈负相关,但与体重指数(BMI)呈正相关。患者与较高剂量的华法林摄入量呈负相关。
本研究得出结论,骨质减少和骨质疏松是槟城华法林使用者和非使用者之间的严重问题。因此,马来西亚卫生部的议程中应予以考虑。